Flamel Technologies SA (FLML.OQ) Quote| Reuters.com
United States

Flamel Technologies SA (FLML.OQ)

FLML.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$0.57 (+5.58%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for FLML.OQ


Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs... (more)


Beta: 1.41
Market Cap(Mil.): $421.49
Shares Outstanding(Mil.): 41.24
Dividend: --
Yield (%): --


  FLML.OQ Industry Sector
P/E (TTM): 91.57 39.54 34.69
EPS (TTM): 0.11 -- --
ROI: 14.95 -6.70 14.13
ROE: 49.24 -6.13 15.35

BRIEF-Flamel Technologies maintains full year 2016 revenue guidance

* Expects research & development expenses to be in range of $35 - $50 million, up from $25.6 million in 2015

May 09 2016

BRIEF-Flamel Technologies gets FDA approval of Akovaz

* Flamel expects to launch Akovaz during Q3 2016 in a strength of 50 mg/ml Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 02 2016

BRIEF-Flamel Tech provides update on trial design for narcolepsy therapy

* Filed spa with fda for pivotal phase iii study of micropump based sodium oxybate product Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

Mar 31 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
Provider : Pechala's Reports
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.